Mazdutide

ID: mazdutide

Aliases: MAZDUTIDE, IBI362, LY3305677

Type: compound

Route/form: subcutaneous injection in trials

Status: investigational

Evidence level: human RCT

Best data tier: human controlled/review

Support scope: human, non-human/mechanistic, review/regulatory

Source types: human_rct, meta_analysis, preclinical, review

Linked sources: 7

Broad outcomes: Fat loss / metabolic health

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• GLP-1 receptor agonist
• glucagon receptor agonist

Optimization domains

• metabolic
• obesity
• diabetes
• MASLD

Research basis

• Human obesity and diabetes trials show clinically meaningful weight and glycemic effects for GLP-1/glucagon dual agonism.
• Glucagon-signaling reviews and mazdutide MASLD animal data give adjacent liver-fat and lipid-metabolism rationale.
• This makes mazdutide a useful comparator to survodutide and retatrutide rather than a generic GLP-1 clone.

Limits, risks, and missing evidence

• It is not approved in the US at this curation point.
• Current human evidence is stronger for obesity/T2D endpoints than for direct liver-histology or performance outcomes.
• GI, heart-rate, gallbladder/pancreatitis class concerns and glucagon-related physiology require trial-context interpretation.

Risk flags

• investigational
• metabolic endocrine
• medical supervision
• injection

Linked papers, labels, and reviews

1. A phase 2 randomized controlled trial of mazdutide in Chinese overweight adults or adults with obesity
   human_rct / pubmed_mazdutide_phase2_obesity_2023
   Human obesity trial for GLP-1/glucagon dual agonist mazdutide.
2. Safety and efficacy of mazdutide 9 mg and 10 mg in Chinese adults with type 2 diabetes
   human_rct / pubmed_mazdutide_t2d_highdose_2022
   Human diabetes/metabolic phase 1b/2 dose context.
3. Once-weekly mazdutide in Chinese adults with obesity or overweight
   human_rct / pubmed_mazdutide_obesity_2025
   More recent human obesity trial record.
4. Mazdutide ameliorates metabolic dysfunction-associated steatotic liver disease by modulating endoplasmic reticulum stress, improving lipid metabolism and alleviating inflammation
   preclinical / pubmed_mazdutide_masld_preclinical_2026
   Direct preclinical MASLD mechanism source for mazdutide; useful adjacent rationale because current human data are mainly obesity/T2D.
5. Shared mechanistic pathways of glucagon signalling: unlocking its potential for treating obesity and MASLD
   review / pubmed_glucagon_signalling_masld_review_2025
   Mechanism review for glucagon agonism as a component of dual/triple agonist metabolic and liver-fat programs.
6. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials
   meta_analysis / pubmed_mazdutide_meta_2024
   RCT meta-analysis of mazdutide weight-loss efficacy and safety across diabetic and non-diabetic adults.
7. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
   human_rct / pubmed_mazdutide_t2d_phase2_china_2023
   Phase 2 T2D trial of mazdutide versus placebo/open-label dulaglutide; adds glycemic, weight, and safety context.